All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): GAD-alum,Vitamin D2
Therapeutic Area: Endocrinology Product Name: Diamyd
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 04, 2021
Details:
The trial is designed to confirm the effect and safety of Diamyd® in individuals recently diagnosed with type 1 diabetes who carry the genetic HLA DR3-DQ2 haplotype.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): GAD-alum,Vitamin D2
Therapeutic Area: Endocrinology Product Name: Diamyd
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 26, 2021
Details:
Results from the phase IIb trial DIAGNODE-2 with intralymphatic administration of Diamyd® and meta-analysis comprising data from more than 600 patients treated with Diamyd® showing treatment effect in individuals carrying the HLA DR3-DQ2 haplotype, will be presented.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): GAD-alum
Therapeutic Area: Endocrinology Product Name: Diamyd
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 19, 2020
Details:
The immunological findings indicate early treatment-specific immune responses that may associate with HLA type and clinical treatment response to Diamyd®.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): GAD-alum
Therapeutic Area: Endocrinology Product Name: Diamyd
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 13, 2020
Details:
Diamyd Medical's Phase IIb trial DIAGNODE-2 with the diabetes vaccine Diamyd is expected to present Topline results at the end of September. All patients in the trial where Diamyd® is given directly into the lymph node have completed their 15-month visits according to plan.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Diamyd
Therapeutic Area: Endocrinology Product Name: Undisclosed
Highest Development Status: Phase II Product Type: Vaccine
Partner/Sponsor/Collaborator: Protein Sciences Corporation
Deal Size: $5.0 million Upfront Cash: $5.0 million
Deal Type: Agreement February 05, 2020
Details:
The agreement facilitates the transition of the manufacturing process of recombinant GAD65, to a new manufacturer for future anticipated commercial manufacture.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
